JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DURHAM, N.C., Oct. 17, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, CEO of Heat is scheduled to present at the following investor conferences:
BIO Investor Forum
Date: Tuesday, October 18, 2016
Time: 3:30 PM Eastern Time
Location: Westin St. Francis Hotel in San Francisco, CA
Main Therapeutic Focus: Immunology
Webcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
The Dawson James Growth Stock Conference
Date: Thursday, October 20, 2016
Time: 10:00 AM Eastern Time
Location: Wyndham Grand Hotel in Jupiter, FL
Webcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
Additionally, Chief Scientific Officer, Taylor Schreiber, M.D., Ph.D., will participate in a panel discussion on “The Sizzling Science and Business of Immuno-Oncology” at the North Carolina Biotechnology Center, on October 25th, from 4-7 PM. For more information on the panel please go to: http://www.ncbiotech.org/event/life-sciences-forum/191426.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: For Investor Inquiries: David Waldman 919-240-7133 [email protected] For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 [email protected]
